Publications

Product Name
Citation
References for ARv7 Splice Variant antibody [RM7]Miao L et al. Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res. (2017) 10.1158/0008-5472.CAN-16-2169. WB; Human. Read more (PubMed: 28302679)

Moon SJ et al. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. Oncogene (2018) 10.1158/0008-5472.CAN-16-2169. WB; Human. IP; Human. ChIP; Human. Read more (PubMed: 29249800)

Zhu Y et al. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol. (2017) 10.1016/j.eururo.2017.08.009. WB; Human. IHC-P; Human. Read more (PubMed: 28866255)

Luo J et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. (2017) 10.1016/j.eururo.2017.11.038. WB; Human. IHC-P; Human. ChIP; Human. Read more (PubMed: 29258679)
References for Histone H3 K27M Mutant antibody [RM192]Pathania M et al. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas Cancer Cell (2017) 10.1016/j.ccell.2017.09.014. IHC-P; Human. Read more (PubMed: 29107533)
References for Histone H3 K36M Mutant antibody [RM193]Amary MF et al. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology (2016) 10.1111/his.12945. IHC-P; Human. Read more (PubMed: 26844533)

Fang D et al. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science (2016) 10.1126/science.aae0065. ChIP; Human. Read more (PubMed: 27229140)

Jundt G et al. Chondroblastoma. Der Pathologe (2018) 10.1007/s00292-017-0397-3. IHC-P; Human Read more (PubMed: 29209799)
References for Histone H3.3 G34W Mutant antibody [RM263]Scotto di Carlo F et al. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location. BMC Cancer (2018) 10.1186/s12885-018-4291-z. IHC-P; Human, IF-P; Human Read more (PubMed: 29609578)

Yamamoto H et al. Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone. Human Pathology (2017) 10.1016/j.humpath.2017.11.020. IHC; Human. Read more (PubMed: 29241742)

Kato I et al. Giant Cell Tumours of Bone Treated with Denosumab: Histologic, Immunohistochemical, and H3F3A Mutation Analyses. Histopathology (2017) 10.1111/his.13448. IHC-P; Human. IF; Human. Read more (PubMed: 29206281)

Luke J et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology (2017) 10.1111/his.13190. IHC-P; Human. Read more (PubMed: 28211081)

Amary F et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. AM J Surg Pathol. (2017) 10.1097/PAS.0000000000000859. IHC-P; Human. Read more (PubMed: 28505000)
References for Histone H3.3 G34R Mutant antibody [RM240]Pathania M et al. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas Cancer Cell (2017) 10.1016/j.ccell.2017.09.014. IHC-P; Human. Read more (PubMed: 29107533)

Yamamoto H et al. Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone. Human Pathology (2017) 10.1016/j.humpath.2017.11.020. IHC; Human. Read more (PubMed: 29241742)
References for Histone H3.3 G34V Mutant antibody [RM307]Yamamoto H et al. Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone. Human Pathology (2017) 10.1016/j.humpath.2017.11.020. IHC; Human. Read more (PubMed: 29241742)
References for BRAF V600E Mutant antibody [RM8]Krishnamurthy A et al. Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers. Int J Mol ImmunoOncol. (2018) 10.18203/issn.2456-3994.IntJMolImmunoOncol20180471. IHC-P; Human. Read more (IJMIO: ISSN: 2456-3994)

Gouravan S et al. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Int J Mol Sci. (2018) 10.3390/ijms19040969. WB; Human. Read more (PubMed: 29570692)

Yang H et al. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene (2017) 10.1038/onc.2016.526. WB; Human. Read more (PubMed: 28263969)


References for Phosphotyrosine Rabbit Monoclonal Antibody [RM111]
Sun Y et al. Neuregulin-1/ErbB4 Signaling Regulates Visual Cortical Plasticity Neuron (2016) 10.1016/j.neuron.2016.08.033. IHC; Mouse. Read more (PubMed: 27641496)

References for 5-hydroxymethylcytosine (5-hmC) antibody [RM236]J Reichmann et al. Dual spindle formation in zygotes keeps parental genomes apart in early mammalian embryos,
bioRxiv (2017) 10.1101/198275. IF; Mouse Read more
References for Histone H3.3 Rabbit Monoclonal Antibody [RM190]Hinchcliffe EH et al. Chromosome missegregation during anaphase triggers p53 cell cycle arrest through histone H3.3 Ser31 phosphorylation Nat Cell Biol. (2016) 10.1038/ncb3348. IF; Human, Monkey. Read more (PubMed: 27136267)
References for Acetyl-Histone H3 (Lys9) antibody [RM161]Li Y et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci USA. (2016) 113(50):14402-14407. ChIP; Human.Read more (PubMed: 27911794)

Bulut-Karslioglu A et al. The Transcriptionally Permissive Chromatin State of Embryonic Stem Cells Is Acutely Tuned to Translational Output. Cell Stem Cell. (2018) 10.1016/j.stem.2018.02.004. WB; Human. Read more (PubMed: 29499153)
References for Acetyl-Histone H3 (Lys18) antibody [RM166]Li Y et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci USA. (2016) 113(50):14402-14407. ChIP; Human.Read more (PubMed: 27911794)
References for Acetyl-Histone H3 (Lys56) antibody [RM179]Li Y et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci USA. (2016) 113(50):14402-14407. ChIP; Human.Read more (PubMed: 27911794)
References for Acetyl-Histone H3 (Lys27) antibody [RM172]Li Y et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci USA. (2016) 113(50):14402-14407. ChIP; Human.Read more (PubMed: 27911794)

Bulut-Karslioglu A et al. The Transcriptionally Permissive Chromatin State of Embryonic Stem Cells Is Acutely Tuned to Translational Output. Cell Stem Cell. (2018) 10.1016/j.stem.2018.02.004. WB; Human. Read more (PubMed: 29499153)